Purified Trypanosoma cruzi specific glycoprotein for discriminative serological diagnosis of South American trypanosomiasis (Chagas' disease)

Lancet. 1983 Oct 22;2(8356):939-41. doi: 10.1016/s0140-6736(83)90453-1.

Abstract

Chagas' disease, leishmaniasis, and Trypanosoma rangeli infection are endemic and their distributions overlap in vast regions of South and Central America. Serological cross-reactivities can confuse epidemiological studies of these infections, and their differential diagnosis has been assigned a high priority by the World Health Organisation. A lectin-affinity-purified, 90,000 molecular weight glycoprotein (GP90) is present in the known principal strains (zymodemes) of Trypanosoma cruzi and absent from Leishmania and T rangeli. Patients with T cruzi infection have antibody to GP90, whereas patients with leishmaniasis do not and the two infections can be distinguished in an ELISA system using this antigen. In a mouse model, the same test can differentiate between T cruzi and T rangeli infections. Antigens purified by affinity chromatography clearly provide a practical basis for very precise, even strain-specific, diagnostic tests.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / analysis
  • Antibody Specificity
  • Chagas Disease / diagnosis*
  • Cross Reactions
  • Diagnosis, Differential
  • Enzyme-Linked Immunosorbent Assay
  • Glycoproteins / immunology*
  • Humans
  • Trypanosoma cruzi / immunology*

Substances

  • Antibodies
  • Glycoproteins